BSG and myocardial ischemia: Targeting extracellular matrix (ECM) degradation is a promising therapeutic approach, given that ischemia-induced ECM proteolytic activation often leads to extensive cardiac cell necrosis, adverse ventricular remodeling, and heart failure.3 In this context, the ECM metalloproteinase inducer (EMMPRIN; CD147, Basigin), a glycoprotein that promotes MMP (matrix metalloprotease)-induced ECM degradation when is highly glycosylated EMMPRIN, is a potential target that plays a key role in the inflammatory response to cardiac ischemia, by regulating the expression of MMP-9 and MMP-13.4–7